{
  "title": "Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialHeart failure with preserved ejection fraction: a reviewHeart failure with preserved ejection fraction:  scientific statementCharacterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fractionAtrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillationCardiovascular effects of relaxin: from basic science to clinical therapyMaternal vasodilation in pregnancy: the emerging role of relaxinRelaxin family peptides and their receptorsRelaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb studySerelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialSerelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialA randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failureEffects of serelaxin in patients with acute heart failureEffects of serelaxin in patients admitted for acute heart failure: a meta-analysisDevelopment of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failurePrevalence and prognostic significance of elevated \u03b3-glutamyltransferase in chronic heart failureIntravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trialImpact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)Electrolyte and water excretion in arterial hypertension. II. Studies in subjects with essential hypertension after antihypertensive drug treatmentRapid blood pressure control with minoxidil: acute and chronic effects on blood pressure, sodium excretion, and the renin-aldosterone systemHigh-output heart failure: a 15-year experienceDisconnect between the effects of serelaxin on renal function and outcome in acute heart failureAltered hemodynamics and end-organ damage in heart failure: impact on the lung and kidneyAlbumin excretion rate increases during acute myocardial infarction and strongly predicts early mortalityAlbuminuria as a marker of systemic congestion in patients with heart failureTrajectory of urine albumin-creatinine ratio in patients with acute heart failureRenal protein excretion after exercise in manProteinuria in children with febrile illnessesB-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failureEstimating left ventricular filling pressure by echocardiographyUncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesityRevivifying research on relaxin receptor-targeted therapy for cardiovascular diseasesNew creatinine- and cystatin C\u2013based equations to estimate GFR without raceRecommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingRecommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingLeft atrial strain performance and its application in clinical practiceNormal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysisLeft atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fractionImpaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fractionLA mechanics in decompensated heart failure: insights from strain echocardiography with invasive hemodynamicsPrognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strainInterpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care:  state-of-the-art reviewEffects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial",
  "pmcid": "12618225",
  "features": {
    "sample_size": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "sample size",
        "n\u2009=\u200926"
      ],
      "examples": [
        {
          "match": "sample size",
          "context": "100-mg dosages together. The sample size was calculated based on the p"
        },
        {
          "match": "sample size",
          "context": "y linked to this article. The sample size was calculated based on the p"
        },
        {
          "match": "n\u2009=\u200926",
          "context": "Participants from that site (n\u2009=\u200926) were excluded from efficacy"
        }
      ]
    },
    "randomization": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "randomly assigned",
        "allocation"
      ],
      "examples": [
        {
          "match": "randomly assigned",
          "context": "pproximately 456 participants randomly assigned to volenrelaxin 25\u2009mg:50\u2009mg:1"
        },
        {
          "match": "randomly assigned",
          "context": "pproximately 456 participants randomly assigned to volenrelaxin 25\u2009mg:50\u2009mg:1"
        },
        {
          "match": "allocation",
          "context": "MRM) with terms for treatment allocation, study visit, treatment-by-vi"
        }
      ]
    },
    "blinding": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "blinded"
      ],
      "examples": [
        {
          "match": "blinded",
          "context": "nes34,35 and interpreted in a blinded fashion at a central core lab"
        },
        {
          "match": "blinded",
          "context": "adjudicated by an independent blinded clinical endpoint committee."
        }
      ]
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "stratification"
      ],
      "examples": [
        {
          "match": "stratification",
          "context": "interaction, baseline value, stratification strata defined by region (Nor"
        },
        {
          "match": "stratification",
          "context": "interaction, baseline value, stratification strata defined by region (Nor"
        }
      ]
    },
    "variable_definitions": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "primary endpoint"
      ],
      "examples": [
        {
          "match": "primary endpoint",
          "context": "central core laboratory. The primary endpoint of this mechanistic trial was"
        },
        {
          "match": "primary endpoint",
          "context": "26\u2009weeks was selected as the primary endpoint of the trial. Secondary endpo"
        },
        {
          "match": "primary endpoint",
          "context": "ference of 4% or more for the primary endpoint. Analysis of efficacy endpoin"
        }
      ]
    },
    "analysis_principles": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": true,
      "count": 16,
      "unique_matches": [
        "adjustment for multiplicity",
        "no adjustment"
      ],
      "examples": [
        {
          "match": "adjustment for multiplicity",
          "context": "ation of 50\u2009mg and 100\u2009mg. No adjustment for multiplicity was performed, and P values s"
        },
        {
          "match": "adjustment for multiplicity",
          "context": "ation of 50\u2009mg and 100\u2009mg. No adjustment for multiplicity was performed, and P values s"
        },
        {
          "match": "adjustment for multiplicity",
          "context": "st square means from MMRM. No adjustment for multiplicity was performed.For NT-proBNP,"
        }
      ]
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 14,
      "unique_matches": [
        "p\u2009<\u20090.05",
        "p\u2009<\u20090.01",
        "secondary endpoint",
        "p\u2009<\u20090.001"
      ],
      "examples": [
        {
          "match": "P\u2009<\u20090.05",
          "context": "m baseline in original scale.*P\u2009<\u20090.05 for change with volenrelaxin"
        },
        {
          "match": "P\u2009<\u20090.01",
          "context": "versus change with placebo; **P\u2009<\u20090.01 for change with volenrelaxin"
        },
        {
          "match": "P\u2009<\u20090.001",
          "context": "ersus change with placebo; ***P\u2009<\u20090.001 for change with volenrelaxin"
        }
      ]
    },
    "confidence_intervals": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "comparative_stats": {
      "present": true,
      "count": 10,
      "unique_matches": [
        "t-test",
        "fisher\u2019s exact",
        "chi-square"
      ],
      "examples": [
        {
          "match": "t-test",
          "context": "n is assessed using two-sided t-test based on least square means f"
        },
        {
          "match": "t-test",
          "context": "was assessed using two-sided t-test based on least square means f"
        },
        {
          "match": "t-test",
          "context": "n is assessed using two-sided t-test based on least square means f"
        }
      ]
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": true,
      "count": 10,
      "unique_matches": [
        "mmrm"
      ],
      "examples": [
        {
          "match": "MMRM",
          "context": "model for repeated measures (MMRM) with terms for treatment all"
        },
        {
          "match": "MMRM",
          "context": "ion (for example, NT-proBNP), MMRM was first applied to the log-"
        },
        {
          "match": "MMRM",
          "context": "model for repeated measures (MMRM) with terms for treatment all"
        }
      ]
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "log-rank"
      ],
      "examples": [
        {
          "match": "log-rank",
          "context": "parison is assessed using the log-rank test. For other clinical even"
        }
      ]
    },
    "regression_and_models": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "cox proportional"
      ],
      "examples": [
        {
          "match": "Cox proportional",
          "context": "comparison is assessed using Cox proportional hazard model. Treatment compa"
        }
      ]
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "categorical",
        "continuous"
      ],
      "examples": [
        {
          "match": "categorical",
          "context": "ltiplicity was performed. For categorical variables, including improved"
        },
        {
          "match": "continuous",
          "context": "atment groups with respect to continuous measurements assessed over ti"
        },
        {
          "match": "continuous",
          "context": "atment groups with respect to continuous measurements assessed over ti"
        }
      ]
    },
    "dependency": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "longitudinal",
        "repeated measures"
      ],
      "examples": [
        {
          "match": "repeated measures",
          "context": "er time was a mixed model for repeated measures (MMRM) with terms for treatme"
        },
        {
          "match": "repeated measures",
          "context": "er time was a mixed model for repeated measures (MMRM) with terms for treatme"
        },
        {
          "match": "longitudinal",
          "context": "lume, left ventricular global longitudinal strain and LA filling pressur"
        }
      ]
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "dropout"
      ],
      "examples": [
        {
          "match": "dropout",
          "context": "n April 2024). Assuming a 20% dropout rate, this would result in ap"
        },
        {
          "match": "dropout",
          "context": "n April 2024). Assuming a 20% dropout rate, this would result in ap"
        }
      ]
    },
    "effect_size": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "or"
      ],
      "examples": [
        {
          "match": "OR",
          "context": "comparison is assessed using OR by Fisher\u2019s exact test or chi"
        },
        {
          "match": "OR",
          "context": "comparison is assessed using OR by Fisher\u2019s exact test or chi"
        }
      ]
    },
    "post_hoc": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "post hoc"
      ],
      "examples": [
        {
          "match": "post hoc",
          "context": "from baseline to week 26. In post hoc mechanistic analyses, all dos"
        },
        {
          "match": "post hoc",
          "context": "from baseline to week 26. In post hoc mechanistic analyses, all dos"
        }
      ]
    },
    "baseline_reporting": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "baseline characteristic",
        "table 1"
      ],
      "examples": [
        {
          "match": "Baseline characteristic",
          "context": "alting of the trial. CAPTION: Baseline characteristics FOOTER: Values show number ("
        },
        {
          "match": "Table 1",
          "context": "scale.Abbreviations are as in Table 1. CAPTION: Physiologic effects"
        },
        {
          "match": "Table 1",
          "context": "acebo.Abbreviations are as in Table 1. CAPTION: Clinical events and"
        }
      ]
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "excluded"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "ntinuation of study drug were excluded. The sponsor identified a ser"
        },
        {
          "match": "excluded",
          "context": "from that site (n\u2009=\u200926) were excluded from efficacy analysis. For s"
        },
        {
          "match": "excluded",
          "context": "ntinuation of study drug were excluded. The sponsor identified a ser"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "sensitivity"
      ],
      "examples": [
        {
          "match": "sensitivity",
          "context": "l injury was assessed by high-sensitivity troponin T. Transthoracic two"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    }
  },
  "feedback": {
    "overall_score": 1.0,
    "rigor_rating": "Low",
    "critical_gaps": [
      {
        "message": "Explicitly stated that no multiplicity correction or formal hypothesis testing was performed.",
        "evidence": "...ation of 50\u2009mg and 100\u2009mg. No adjustment for multiplicity was performed, and P values s..."
      },
      {
        "message": "Parametric tests used without documented normality checks.",
        "evidence": "...n is assessed using two-sided t-test based on least square means f..."
      },
      {
        "message": "Blinding present but allocation concealment details missing.",
        "evidence": "...nes34,35 and interpreted in a blinded fashion at a central core lab..."
      },
      {
        "message": "P-values reported without effect sizes (e.g. Odds Ratio).",
        "evidence": "...m baseline in original scale.*P\u2009<\u20090.05 for change with volenrelaxin..."
      },
      {
        "message": "Includes exploratory/post hoc analyses without clear multiplicity correction.",
        "evidence": "...from baseline to week 26. In post hoc mechanistic analyses, all dos..."
      },
      {
        "message": "Paired data mentioned but no paired statistical tests found.",
        "evidence": "...er time was a mixed model for repeated measures (MMRM) with terms for treatme..."
      },
      {
        "message": "Longitudinal/clustered data detected without hierarchical modeling.",
        "evidence": "...er time was a mixed model for repeated measures (MMRM) with terms for treatme..."
      },
      {
        "message": "Survival analysis used without verifying proportional hazards assumption.",
        "evidence": "...parison is assessed using the log-rank test. For other clinical even..."
      },
      {
        "message": "P-values reported only as thresholds (e.g., P<0.05).",
        "evidence": "...m baseline in original scale.*P\u2009<\u20090.05 for change with volenrelaxin..."
      }
    ],
    "strengths": [
      {
        "message": "Used Mixed Models (MMRM/GLMM) which can handle missing data under MAR.",
        "evidence": "...model for repeated measures (MMRM) with terms for treatment all..."
      },
      {
        "message": "Blinding of participants/assessors documented.",
        "evidence": "...nes34,35 and interpreted in a blinded fashion at a central core lab..."
      },
      {
        "message": "Exclusion criteria explicitly defined (transparency).",
        "evidence": "...ntinuation of study drug were excluded. The sponsor identified a ser..."
      },
      {
        "message": "Reported diagnostic metrics (AUC/ROC).",
        "evidence": "...l injury was assessed by high-sensitivity troponin T. Transthoracic two..."
      }
    ],
    "actionable_recommendations": [
      {
        "item": "Multiplicity",
        "issue": "Lack of correction increases Type I error.",
        "recommendation": "Use Bonferroni or FDR, or label as exploratory.",
        "source_text": "adjustment for multiplicity no adjustment"
      },
      {
        "item": "Assumptions",
        "issue": "Parametric tests assume normality.",
        "recommendation": "Report Shapiro-Wilk/KS test or use non-parametric tests.",
        "source_text": "Found parametric tests: t-test"
      },
      {
        "item": "Allocation Concealment",
        "issue": "Method of concealment (e.g. opaque envelopes) not described.",
        "recommendation": "Specify how randomization sequence was concealed.",
        "source_text": "Blinding found but no 'concealment' terms."
      },
      {
        "item": "Deductive Rigor",
        "issue": "Post hoc findings are hypothesis-generating.",
        "recommendation": "Distinguish between pre-specified endpoints and exploratory analyses.",
        "source_text": "Found term 'post hoc' without rigorous correction."
      },
      {
        "item": "Statistical Architecture",
        "issue": "Clustered/repeated data requires hierarchical models.",
        "recommendation": "Use LMM, GLMM, or GEE.",
        "source_text": "Found 'longitudinal' but no mixed-effects models."
      }
    ],
    "deterministic_audit": true
  }
}